AngioSoma Financial Statements From 2010 to 2024
| GSTC Stock | USD 0.0003 0.0001 50.00% |
Check AngioSoma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AngioSoma's main balance sheet or income statement drivers, such as , as well as many indicators such as . AngioSoma financial statements analysis is a perfect complement when working with AngioSoma Valuation or Volatility modules.
AngioSoma |
AngioSoma Company Shares Outstanding Analysis
AngioSoma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current AngioSoma Shares Outstanding | 770.36 M |
Most of AngioSoma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AngioSoma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, AngioSoma has 770.36 M of shares currently outstending. This is 326.71% higher than that of the sector and significantly higher than that of the Shares Outstanding industry. The shares outstanding for all United States stocks is 34.72% lower than that of the firm.
AngioSoma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AngioSoma's current stock value. Our valuation model uses many indicators to compare AngioSoma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AngioSoma competition to find correlations between indicators driving AngioSoma's intrinsic value. More Info.AngioSoma is rated below average in return on asset category among its peers. It also is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value AngioSoma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AngioSoma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About AngioSoma Financial Statements
AngioSoma stakeholders use historical fundamental indicators, such as AngioSoma's revenue or net income, to determine how well the company is positioned to perform in the future. Although AngioSoma investors may analyze each financial statement separately, they are all interrelated. For example, changes in AngioSoma's assets and liabilities are reflected in the revenues and expenses on AngioSoma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AngioSoma. Please read more on our technical analysis and fundamental analysis pages.
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was incorporated in 2016 and is based in Richland, Washington. Globestar Therapeutics is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AngioSoma Pink Sheet
AngioSoma financial ratios help investors to determine whether AngioSoma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AngioSoma with respect to the benefits of owning AngioSoma security.